This edition of JAMA Internal Medicine has also featured a study evaluating the re-design of prescribing systems which feature medicines listed by generic name, together with a survey of physicians’ beliefs around the effectiveness of generic medicines compared to branded products.
A related editorial also discusses the implications of the findings of these studies, and notes that the studies in this issue show great progress—but also great risks—for the generic drug industry in the United States.